MajesTEC-7

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

What will happen during the trial?

More Information

Trial Status
Accepting patients
Trial Phase
Phase 3
Enrollment
1,590 patients (estimated)
Tags
Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3, Randomization
Trial Type
Treatment
Last Update
SparkCures ID
1312
NCT Identifier
NCT05552222

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.